Savara (NASDAQ:SVRA) Shares Gap Down – Here’s Why

Savara Inc. (NASDAQ:SVRA) shares gapped down before the market opened on Monday . The stock had previously closed at $6.29, but opened at $5.72. Savara shares last traded at $5.9150, with a volume of 783,862 shares trading hands.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on SVRA. Lifesci Capital raised Savara to a “strong-buy” rating in a research report on Tuesday, October 14th. Citigroup restated an “outperform” rating on shares of Savara in a research report on Thursday, October 23rd. Guggenheim upped their target price on Savara from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Tuesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Savara in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Savara presently has an average rating of “Moderate Buy” and an average price target of $8.29.

Savara Stock Down 6.8%

The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. The business has a 50-day simple moving average of $4.07 and a two-hundred day simple moving average of $3.19. The stock has a market capitalization of $1.19 billion, a P/E ratio of -11.67 and a beta of 0.45.

Savara (NASDAQ:SVRA) last issued its earnings results on Wednesday, November 12th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Equities research analysts forecast that Savara Inc. will post -0.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the business. Russell Investments Group Ltd. boosted its stake in Savara by 930.5% in the third quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after purchasing an additional 9,463 shares in the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Savara in the third quarter valued at about $44,000. Prudential Financial Inc. bought a new position in shares of Savara in the second quarter valued at about $30,000. BNP Paribas Financial Markets lifted its position in Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company’s stock worth $31,000 after buying an additional 4,626 shares in the last quarter. Finally, May Hill Capital LLC bought a new stake in Savara during the 2nd quarter worth about $32,000. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.